Matthew Krebs, MBChB, PhD, explains the rationale for a phase II study of bemcentinib, a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced non–small cell lung cancer, which he presented at the 2019 Society for Immunotherapy of Cancer Annual Meeting.
Matthew Krebs, MBChB, PhD, a clinical senior lecturer in Experimental Cancer Medicine at the University of Manchester, explains the rationale for a phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab (Keytruda) in patients with advanced nonsmall cell lung cancer, which he presented at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
AXL drives epithelial-mesenchymal transition and resistance to cytotoxic T-cell mediated cell death. If AXL inhibition is administered in the preclinical setting, the AXL positivity can be reduced, making the cells more susceptible to T-cell-mediated killing. This ability is what makes AXL inhibitors ideal for combination with immune checkpoint inhibitors, says Krebs.
Additionally, in vivo models that evaluated bemcentinib in combination with immune checkpoint inhibitors demonstrated synergy between these two types of therapy in lung cancer and in other malignancies.
For more about the phase II study from SITC 2019:https://www.targetedonc.com/news/adjuvant-immunotherapy-combination-shows-activity-in-axlpositive-nsclc
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More